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ARTICLE 
Untying a Nanoscale Knotted Polymer Structure to 
Linear Chains for Efficient Gene Delivery In Vitro 
and to the Brain 
B. Newland,a A. Aied,a A. V. Pinoncely,a Y. Zheng,a T. Zhao,a H. Zhang,a R.
Niemeier,a E. Dowd,b A. Pandit*,a W. Wang*a
The purpose of this study was to develop a platform transfection technology, for applications 
in the brain, which could transfect astrocytes without requiring cell specific functionalization 
and without the common cause of toxicity through high charge density. Here we show that a 
simple and scalable preparation technique can be used to produce a “knot” structured cationic 
polymer, where single growing chains can crosslink together via disulphide intramolecular 
crosslinks (internal cyclizations). This well-defined knot structure, can thus “untie” in reducing 
conditions, showing a more favorable transfection profile for astrocytes than 25kDa-PEI (48-
fold), SuperFect® (39-fold) and Lipofectamine®2000 (18-fold) whilst maintaining neural cell 
viability at over 80% after four days of culture. The high transfection/lack of toxicity of this 
knot structured polymer in vitro, combined with its ability to mediate luciferase transgene 
expression in the adult rat brain, demonstrate its use as a platform transfection technology 
which should be investigated further for neurodegenerative disease therapies.  
Introduction 
A variety of nanoscale materials have been used to deliver 
nucleic acids into cells, for example nanoparticles,1 gold 
nanorods2 and functionalized carbon nanotubes.3 These 
materials vary greatly in chemical composition, structure, 
physical properties and aspect ratio, and thus vary in delivery 
efficiency. Cationic polymers, also studied extensively for 
applications in gene delivery, show a high dependency of 
transfection capability on the polymer structure, even when the 
molecular composition is almost the same. For example, when 
branching is introduced into 2-(dimethylamino)ethyl 
methacrylate (DMAEMA) based polymers the transfection 
capability vastly increases compared to linear DMAEMA.4, 5  
Living free radical polymerizations offer an attractive 
means to design and synthesize different structured polymers 
for applications in nucleic acid delivery.6 Polymerizations such 
as reverse addition-fragmentation chain transfer polymerization 
(RAFT) or atom transfer radical polymerization (ATRP) can be 
used to synthesize linear homopolymers and copolymers such 
as block, comb and star shaped polymers. 
Branched/hyperbranched polymers, typically effective for 
nucleic acid delivery, require branching monomers or 
multifunctional monomers (MFM) to produce branch points. 
However, the Flory-Stockmayer theory statistically determines 
that the use of MFMs will inevitably lead to crosslinking and 
gelation.7, 8 These MFMs can therefore only be incorporated in 
very small amounts (typically less than 1%)9 resulting in few 
branch points among long linear chains.10 In contrast, our 
recently proposed kinetic theory, introduced to supplement the 
Flory-Stockmayer theory, suggests that actually MFMs can be 
used in large proportions (even homopolymerisation) if the 
boundary of a growing chain in any active cycle is kept very 
small.11 Thus, in a reaction such as deactivation enhanced 
ATRP (DE-ATRP), a reduced instantaneous growth boundary 
can be obtained whereby growing chains of MFM no longer 
crosslink to different chains (intermolecular crosslinks) until 
much later in the reaction process.11 Instead single chains grow 
and link to themselves (intramolecular cyclisations) to form a 
single cyclized knot polymer structure. 
We have previously demonstrated the gene delivery 
potential of non-degradable single cyclized knot structures over 
a range of cell types.12 The 3-dimentional polymer structure 
does result in a high transfection capability but the associated 
toxicity increased when the molecular weight of the knots 
reached a level suitable for optimal transfection (25-30kDa). A 
vast improvement over the previous knot polymer was sought, 
that would not show cellular toxicity at the required 
polymer/plasmid ratio, but would remain highly efficient, thus 
breaking the trend of the vehicle efficiency/toxicity 
relationship. It was hypothesized that a high molecular weight 
knot structure, with cleavable crosslinks, would allow for the 
high transfection capability associated with the dense 3D 
structure, but maintain cellular viability via polyethylene glycol 
(PEG) units and intracellular cleavage (untying to linear 
chains). Lastly, it was desired to analyse whether this 
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transfection agent could provide a platform technology for use 
in the context of brain/central nervous system (CNS) 
applications through its simplicity, scalability and option of 
post synthesis modifications. 
Experimental 
Materials
The monomers 2-(dimethylamino)ethyl methacrylate 
(DMAEMA) and poly(ethylene glycol) methyl ethyl 
methacrylate (PEGMEMA) were purchased from Sigma 
Aldrich. The third monomer, composed of a disulphide linked 
dimethacrylate (DSDMA), was synthesized as previously 
reported by Li and Armes.13 The reagents bis(2-hydroxyethyl) 
disulfide (BHEDS), triethylamine and methacryloyl chloride 
for DSDMA synthesis were purchased from Sigma Aldrich. N-
pentamethyldiethylenetriamine (PMDETA, 99%), ethyl 2-
bromoisobutyrate (EBriB, 98%), copper(II) chloride (CuCl2, 
97%), d-Chloroform (99.8%), L-ascorbic acid (AA, 99%) and 
hydrochloric acid (HCl, 37%) were used as received from 
Sigma Aldrich. 2-Butanone (HPLC grade, LabScan), 
tetrahydrofuran (THF, HPLC grade, Fisher), n-hexane (ACS 
reagent grade, Fisher), dichloromethane (ACS reagent grade, 
Fisher) and dimethylflormamide (DMF, HPLC grade, Fisher) 
were used as received. For analysis of the polyplexes, agarose 
(for electrophoresis, Aldrich), SYBR® Safe Gel stain 
(Invitrogen), BioLux™ Gaussia Luciferase Assay Kit (New 
England Biolabs), alamarBlue® (Invitrogen) were used as 
received and according to manufacturers’ protocols. 
Synthesis of DSP8
In situ deactivation enhanced atom transfer radical 
polymerization (DE-ATRP) was used to allow sufficient 
control for intramolecular cyclization to occur. The initiator 
EBriB (9.2 mg, 1 molar equivalent), the catalyst CuCl2 (3.8 mg, 
0.6 molar equivalent) and the catalyst ligand PMDETA (4.9 
mg, 0.6 molar equivalent) were added into a 2-necked round 
bottom flask. Monomers were added in the following ratio: 
DMAEMA 5.95 g, 820 molar equivalents, PEGMEMA 1.75 g, 
80 molar equivalents and DSDMA 0.91 g, 100 molar 
equivalents. After removal of oxygen, 20 µl of 36mg/ml 
AA(aq), 0.09 molar equivalent was added under positive 
pressure of argon to begin the polymerization at 40oC with 
stirring set at 800rpm (flask suspended in a pre-heated oil bath). 
The reaction was stopped by opening the flask to the air and 
swirling the contents to allow oxygen through the liquid. 
Purification of DSP8
All stages of the following purification process were performed 
in the absence of direct light where possible. The polymer was 
diluted in THF, then precipitated using an excess of vigorously 
stirring hexane. The hexane was then removed and the polymer 
was left to dry under laminar flow. This was then re-dissolved 
in acetone and the pH was reduced to 5 by adding 1M HCl 
before immediate dialysis against dH2O using a Spectrapor® 
dialysis membrane (6000-8000 MWCO) for several days. 
Finally the polymer was freeze dried to a white powder for 
subsequent analysis. 
Determination of Molecular Weight
During the reaction process, 1 ml samples were extracted under 
positive argon pressure for gel permeation chromatography 
(GPC) analysis of the molecular weight. The samples were 
diluted in DMF then filtered through aluminia for 
chromatography then through a 0.2 µm pore filter. The 
molecular weight and polydispersity index of each sample was 
determined using a Varian 920-LC instrument with a refractive 
index detector. DMF was used as the eluent and chromatograms 
were run at 50°C using with a flow rate of 1 ml/min. The 
machine was calibrated with linear polystyrene standards.The 
main text of the article should go here with headings as 
appropriate. 
1H-Nuclear Magnetic Resonance (NMR) Spectroscopy Analysis
A sample of the polymer was dissolved in 2 ml of D2O for 1H-
NMR analysis at 300 MHz using a Bruker spectrometer. All 
chemical shifts are reported in ppm relative to TMS. 
Polyplex Characterisation
Gaussia princeps luciferase plasmid DNA (pCMV-G Luc) was 
purchased from New England BioLabs, and was expanded and 
purified using the Giga-Prep (Qiagen) kit as per protocol. The 
polyplex formed with pCMV-G Luc and DSP8 were 
characterized by gel electrophoresis and size/charge analysis. 
Polyplexes were formed using 10 µg of plasmid DNA, and 
varying weight ratios of polymer, made to a final volume of 
100 µl in H2O for size analysis with a zetasizer (Malvern 
Instruments). Each sample was then diluted with H2O to a total 
of 700 µl for charge analysis. Three repeat experiments were 
made for size charge analysis and an average value plotted. 5 µl 
of this polyplex solution was added to 5 µl of loading buffer 
and added to wells of a 0.8% agarose gel in Tris-borate-EDTA 
(TBE) buffer with SYBR®Safe DNA stain and subjected to 80 
mV for 20 minutes. The movement of the DNA through the 
gels was visualized using a G:Box (Syngene) and associated 
GeneSnap software. 
Cytotoxicity Analysis
The LC50 values were calculated for the polymers PEI and 
DSP8 by adding varying concentrations of polymer solutions 
(made up in the normal growth media) to Neu 7 astrocytes for 
24 hours and analysing the cell viability at each concentration 
using the alamarBlue® reduction technique described in the 
following section. The concentration that caused a 50% 
decrease in cell viability (LC50) was read from the cell viability 
vs polymer concentration plot and recorded.  
In addition the LIVE/DEAD® Cell Viability (Molecular 
Probes®) assay was carried out according to the manufacturer’s 
protocol, on Neu 7 cells seeded on poly-L-lysine coated glass 
coverslips, 24 hours after polyplex or naked DNA treatment. 
The assay measures intracellular esterase activity via green-
fluorescent calcein-AM and membrane integrity via red-
fluorescent ethidium homodimer-1. 
Transfection and Cytotoxicity Analysis
The Neu 7 astrocyte cell line was cultured in low glucose 
Dulbecco’s Modified Eagles Medium (DMEM)(Sigma Aldrich) 
supplemented with filtered fetal bovine serum 10% (FBS) 
(Sigma Aldrich) and 1% Penicillin/Streptomycin (P/S) (Sigma 
Aldrich) at 37oC, 5% CO2 humidified atmosphere and using 
standard sterile techniques. 24 hours prior to experimentation, 
 the cells were trypsinized, and seeded at a density of 10,000 
cells/well in a 96-well plate. 10 µl of polyplexes, containing 1 
µg of DNA, were made up in dH2O as described above and 
added to the 100 µl of the media in each well of the 96-well 
plate. All experiments were therefore carried out in the 
presence of serum. After 24 hours of incubation with the 
polyplexes the media was removed for analysis using the G-
Luciferase enzymatic assay (New England BioLabs) according 
to the manufacturer’s protocol. The luminescence was 
immediately read using a Varioskan plate reader (Thermo 
Scientific). In the meantime, to analyse the cell viability, the 
cells in the test well were washed with Hanks Balanced Salt 
Solution (HBSS)(Sigma Aldrich) and 100 µl of a 10% 
alamarBlue® solution in HBSS was added to each well and 
incubated for a further three hours. The absorbance of the 
reduced solution was then read at 595 and 550nm and 
converted to a percentage of cell viability by normalizing to the 
Naked DNA treatment group. For the time course study, the 
100 µl of cell supernatant was removed at day 1,2 and 4 for 
analysis, each time being replaced with 10% alamarBlue® 
solution in HBSS for the cytotoxicity analysis, followed by a 
wash and fresh media applied until the next time point. 
Transfection Analysis in the Rat Brain
All procedures were approved by the Animal Ethics Committee 
of the National University of Ireland, Galway and were carried 
out in accordance with the European Communities Council 
Directive (86/609/EEC). A total of 12 adult male Sprague 
Dawley rats (Charles Rivers, UK) weighing between 250-275g 
on the day of surgery were used and randomly assigned to 
groups for intraventricular injections. Rats were deeply 
anesthetised using gaseous isoflurane (2-5% in oxygen), and 
mounted via ear and teeth bars. Bilateral injections into the 
lateral ventricles were made via the following stereotactic 
coordinates: Anteroposterior -0.9 mm, Mediolateral ±1.6 mm 
(from Bregma) and Dorsoventral -3.5 mm (from Dura). 2µl of 
naked DNA or polyplexes containing 1 µg of DNA prepared in 
dH2O was delivered to each injection site. Delivery was 
controlled at a rate of 1µg/min by a syringe pump, and the 
cannula remained in place for an additional two minutes to 
allow diffusion from the cannula tip before removal. 
Tissue Processing
48 hours post injection, rats were deeply anesthetized by 
intraperitoneal injection of pentobarbital (100 mg per kg 
bodyweight) followed by decapitation. Brains were 
immediately removed and frozen immediately over dry ice. The 
brains were later thawed, the cerebellum and olfactory bulbs 
were removed, the hemispheres were then divided and 
homogenised individually in 1 ml of Cell-LyticTM lysis buffer 
(Sigma Aldrich). 100 µl of each sample was then analyzed 
using the luciferase assay kit as per manufacturer’s protocol. 
Statistical Analysis
GraphPad Prism 5 software was used to perform all statistical 
analyses. A one way ANOVA was performed using Tukey’s 
post hoc test to compare all groups. P values < 0.05 were 
considered significantly different. For the in vivo analysis an 
ANOVA was performed with a Dunn’s multiple group analysis, 
P values < 0.05 were considered significantly different. 
Results and Discussion 
 
Scheme 1 shows a depiction of the DE-ATRP reaction process 
used to form the knot polymer. The disulphide dimethacrylate 
monomer (DSDMA) shown in Scheme 1 and SI Figure 1 
(Supporting Information) was synthesized as previously 
described by Li and Armes.13 DSDMA, DMAEMA and 
polyethylene glycol methyl ether methacrylate (PEGMEMA) 
were combined in the following ratio 10:82:8 respectively. The 
monomer to initiator (ethyl 2-bromoisobutyrate) ratio was 
1000:1 to produce a predominantly single chains knotted to 
themselves (cyclized knot structure). During the reaction 
process, single chains grow, and due to both the presence of di-
vinyl monomers and the reduced growth boundary effect 
mediated by DE-ATRP, these chains only crosslink to 
themselves. This forms a single chain knotted to itself in via 
intramolecular crosslinks every 18 monomers of the chain 
(5.6% branching – see Supplementary Table S1). This synthesis 
strategy results in a polymer with low polydispersity even at 
high molecular weights (PDI = 1.44, Mw= 30 kDa) (see 
Supplementary Information Table S2), with molecular weight 
increasing almost linearly with monomer conversion (Figure 1 
insert). The gel permeation chromatography (GPC) peaks 
remain narrow and highly symmetrical throughout the growth 
process. Careful examination of each peak shows that the tails 
of each (right hand side (lowest Mw)) shift to the left as would a 
growing linear chain. During chain combination 
(hyperbranched polymers), this typically remains more static 
and the peaks broaden as the polymers become ever-more 
polydisperse10. However, in our system, the PDI remains low, 
and the peaks move uniformly to the right as would a linear 
grown. This linear-like chain growth, although seemingly like 
that of the growth of a linear polymer, does in fact result in 
approximately one third of the di-vinyl monomers being used 
as branching agents (therefore within the same chain) 
(Supplementary Table S1) thus the formation of the single 
cyclized knot; henceforward termed DSP8 (with 8 representing 
the percentage PEG feed ratio).  
Scheme 1 Formation of the cyclized knot polymer via DE-ATRP. The 
monomers disulphide dimethacrylate (DSDMA), 2-(dimethylamino) 
ethyl methacrylate (DMAEMA) and poly(ethylene glycol) methyl ether 
methacrylate (PEGMEMA) form a single growing chain that crosslinks 
to itself (intramolecular crosslinks) via DSDMA. The scheme depicts 
this single growing chain and how it can link to itself, although the final 
structure is of course not symmetrical or ordered as shown graphically. 
Figure 1 Controlled growth of the knot structure. Gel permeation 
chromatography peaks and corresponding schematic diagrams (though 
no order or symmetry assumed in the knot structure) of samples taken 
during the reaction stages show the formation of the single cyclized 
knot through intramolecular crosslinks (depicted in red) after six hours 
(Mw = 30.0 kDa, PDI = 1.44). Note the shift of the peak tails towards 
the left and the graphical insert of Mw change vs percentage conversion, 
both showing the linear like growth of single chains. 
Figure 2 Untying the knot. Gel permeation chromatography peaks and 
schematic diagrams shows the change in molecular weight after treating 
the polymer samples with 20 µM glutathione (GSH). Cleaving the 
intramolecular crosslinks (depicted in red) effectively unties the knot 
structure resulting in little change in the molecular weight, but a shift of 
the peak molecular weight (Mp) to the left as the untied knot has a 
larger hydrodynamic volume. 
1H NMR spectroscopy analysis of DSP8 reveals free vinyl 
groups (11.6%) are also present in the knot structure 
(Supplementary Table S1). This vinyl functionality could 
potentially be used for attaching targeting moieties or adding 
end capping agents through Michael type addition. Degradation 
of the purified polymer in 20 µM glutathione or 20 µM tris(2-
carboxyethyl) phosphine (TCEP) did not result in a large 
decrease in molecular weight (from 25.3 kDa to 24.4 kDa, 
(Figure 2) as the intramolecular knot crosslinks were cleaved. 
In fact there was an increase in the peak molecular weight (Mp) 
from 20.7 kDa to 28.2 kDa showing the increase in 
hydrodynamic volume (less density) occupied by the untied  
Figure 3 Polyplex characterisation: a) shows retardation of DNA 
through the agarose gel at all polymer/plasmid weight ratios analyzed 
along with PEI (2:1 w:w) polyplexes, SuperFect® (8:1 w:w) polyplexes 
and Lipofectamine 2000 (3:1 w:w) lipoplexes. Surface charge increased 
upon increasing polymer to plasmid ratio b), and polyplex sizes, via 
dynamic light scattering, vary with little apparent trend c). 
linear chains. It should be noted here that this polymer structure 
is distinctly different from either linear,14 hyperbranched15 or 
dendrimer cations16 traditionally used for non-viral gene 
transfection. It is the product of a highly controlled reaction 
involving only the addition of monomers to the growing chain, 
or internal cyclization reactions. 
The electrostatic interaction between cationic polymers and 
negatively charged nucleic acids condenses the genetic material 
into nanoscale particles (polyplexes). Polyplexes formed with 
knot polymers typically show high resistance to DNase 
degradation12, 17 and were characterised here in terms 
electrophoretic mobility, size and charge. Figure 3a shows that 
polyplexes could successfully be formed at a 2:1 polymer to 
plasmid weight ratio, or higher, as shown by the hindrance of 
mobility through the agarose gel. Size/charge analysis (Figure 
3b and c) showed polyplexes increased in charge with 
increasing polymer/plasmid ratio (between 25 and 60 mV) but 
showed a variety of sizes between (70-150 nm). 
The ability to transfect “hard to transfect” tissue such as the 
brain or CNS could have profound implications for the future 
treatment of neurodegenerative disorders such as Alzheimer’s 
disease and Parkinson’s disease. Astrocytes are a predominant 
cell type of the brain, present in proximity to dopaminergic 
neurons (those lost in Parkinson’s disease). Studies have 
therefore focused on the delivery of secreted growth factors 
such as glial cell line-derived neurotrophic factor (GDNF) 
encoding DNA to surrounding astrocytes, rather than to 
neurons themselves.17 However, transfection of astrocytes can 
be difficult, necessitating specific tailoring of the polymer 
composition.18 Transfection of the neuronal cell types by non-
viral means remains a difficult challenge, one which has seen a 
shift of focus towards silencing RNA technology3, 19, 20 because 
of the relative ease of silencing the translation of mRNA into  
 protein. However, overexpression of therapeutic genes/proteins 
in the degenerating brain holds significant promise and should 
not be overlooked.21, 22 
The Neu 7 astrocyte cell line used to analyse the 
cytotoxicity and transfection capability of DSP8 was developed 
as an astrocyte that produces a neuroinhibitory environment,23 
somewhat typical to that of damaged CNS tissue. Previous 
studies have shown Neu 7 astrocytes to be amenable to 
transfection17 so they were chosen for the following studies to 
analyze the performance of the knot polymer in comparison to 
commercially available polymers. Whilst improving the 
transfection efficiency of non-viral vectors remains a necessity, 
analysis of the material toxicity is of equal importance. 
Nanoscale materials may have safety issues due to a high aspect 
ratio24 or an inherent charge density, causing toxicity to the 
brain.25 Thus, the toxicity of DSP8 was specifically studied via 
combination of methods in polyplex form or free solution.  
The concentration at which DSP8 causes a 50% reduction in 
cell viability (LC50) was measured in comparison to 25kDa 
branched polyethyleneimine. Polymer solutions, without being 
complexed to DNA, were analysed using the alamarBlue® 
assay 24 hours after the addition of concentrations ranging from 
1 µg/ml to 500 µg/ml. Figure 4a shows a large difference 
between the toxicity profile of DSP8 (LC50 = 339 µg/ml) 
compared to PEI (LC50 = 11 µg/ml). This elevated toxicity of 
PEI could also be observed for PEI polyplexes formed with 1 
µg of DNA, as observed in the fluorescent micrographs of the 
LIVE/DEAD® assay (Molecular Probes®) (Figure 4b), whereby 
dead cells, stained with red-fluorescent ethidium homodimer-1 
were present and there were large areas cleared of green-
fluorescent calcein-AM stained healthy cells. SuperFect® 
polyplexes (Figure 4c) allowed a greater portion of live cells 
then PEI polyplexes, but had more dying cells than DSP8 
polyplexes (Figure 4d). Both PEI and SuperFect® have no 
cleavable units nor the ability to biodegrade.  However, due to 
the presence of disulfide bonds within the polymer structure, it 
is likely that DSP8 changes conformation upon cell entry. Less 
dense linear chains should form, exhibiting low toxicity. This 
vast difference in cytotoxicity could have large implications for 
the clinical translation of such non-viral vectors, where lack of 
toxicity will be of paramount importance. 
Figure 4 Cytotoxicity of DSP8 towards Neu7 astrocytes in comparison 
to control transfection agents. a) Determination of the LC50 value for 
DSP8 in comparison to PEI using increasing concentrations of the 
polymer solution and the alamarBlue® assay. Representative images of 
LIVE/DEAD® analysis following treatment with polyplexes formed 
with b) PEI, c) SuperFect® or d) DSP8, 24hours post treatment, n=4.  
Figure 5 Transfection and cell viability analysis with Neu 7 astrocytes. 
Luciferase transgene levels 24 hours post transfection a) or up to four 
days post transfection b) with the knot polymer DSP8 in comparison to 
commercially available controls. Cell viability analysis 24 hours c) or 
up to four days d) post transfection (3:1 ratio for DSP8) as analyzed 
using the alamarBlue® assay. Four days post transfection, DSP8 
exhibited 48, 39 and 17 fold higher transgene expression than PEI, 
SuperFect® and Lipofectamine® 2000 respectively, and two fold 
increase in cell viability over PEI and SuperFect. All studies carried out 
in the presence of serum, n=4, symbols mark statistically significant 
difference (P<0.05) from PEI (*), SuperFect® (†), and Lipofectamine® 
2000 (‡) (one way ANOVA, Tukey’s post hoc analysis). 
The transfection capability and cytotoxicity of the polyplexes 
formed with DSP8 were then analysed over a period of four 
days. The duration of transgene expression was investigated, 
because, for applications for neurological disorders, extended 
transgene expression time would be favourable.26 Figure 5a 
shows that as early as 24 hours post administration, all bar one 
of the weight ratios for DSP8 gave significantly higher 
luciferase transfection levels than the “gold standard” branched 
25kDa PEI. Furthermore, Figure 5b shows that at two days and 
four days post transfection the luciferase expression levels 
produced by DSP8 polyplexes are far higher than those of PEI, 
the SuperFect® PAMAM dendrimer and the commonly used 
lipid based Lipofectamine® 2000. Two days post transfection 
DSP8 luciferase levels are 111 times, 50 times, and 14 times 
higher than PEI, SuperFect® and Lipofectamine® 2000 
respectively. By four days post transfection the DSP8 luciferase 
levels had decreased slightly, but were still 48 times, 39 times 
and 18 times that of PEI, SuperFect® and Lipofectamine® 2000 
respectively.  
Whilst much research results in incremental gains in the 
performance of non-viral gene vectors, this knot structure 
shows a profound increase in the luciferase expression 
compared to current commercially available transfection 
agents. The luciferase expression levels produced by the knot 
polymer and Lipofectamine® 2000 stay approximately level 
over the analysis period, but the expression due to the PEI and 
SuperFect® controls decreases, presumably through the toxicity 
mediated by these polymers. Figure 5c shows that over 80% 
cell viability is maintained after the addition of DSP8 
polyplexes (containing 1 µg of DNA per well) at the 
Figure 6 Luciferase transgene activity in the rat brain. Direct 
intraventricular delivery (depicted in a)) of DSP8 polyplexes at a ratio 
of 1.5:1 resulted in a 7.4% increase in luciferase activity over the naked 
DNA control b). n=3, * marks statistically significant difference 
(p<0.05) from naked DNA group (Kruskall-Wallis test with Dunn’s 
multiple group analysis, p=0.0390, Kruskall-Wallis statistic = 6.489). 
 polymer/plasmid ratios tested which are all statistically 
significantly different to that of PEI (40% viability) and 
SuperFect® (57% viability). This improved cell viability is also 
observed at the two and four day time points post transfection 
(Figure 5d). 
Research into the development of non-viral vectors for 
applications in neurodegenerative diseases has more recently 
focused on the addition of a variety of moieties to improve the 
transfection process.27 Molecules such as transferrin have been 
used to aid delivery across the blood brain barrier28 or to 
increase the transfection capability of liposomes stereotactically 
injected into the rodent brain.19 Neuron targeting moieties such 
as Tet1 have also been added to polymeric vectors allowing 
greater neuronal cell transfection than unmodified polymers.29 
However, despite these continual incremental improvements 
shown by the post synthesis addition of moieties, we aimed to 
synthesize and analyse a platform transfection technology that 
would be highly effective in an unmodified form.  
The ability to design a platform transfection technology, 
which could be simple to synthesize, but allow individual 
tailoring to specific target tissues was desired. Thus the ability 
of DSP8 to mediate luciferase expression in the brain was 
analysed via direct stereotactic injection into the lateral 
ventricle (connecting large areas within the brain). Figure 6 
shows that the administration of DSP8 polyplexes directly into 
the ventricle of the adult Sprague Dawley rat mediates a 7.4% 
increase in the level of transgene expression over naked DNA 
two days post injection. A previous study by Pun and co-
workers has shown that non-viral transfection can be achieved 
in the rodent brain via intraventricular injection, which 
occurred predominantly in the subventricular zone.29 Figure 6b 
shows that an increased level of transfection can be achieved 
using DSP8 at a polymer plasmid ratio of 1.5 to 1 (w:w). The 
increase in transgene expression observed, proves the concept 
that non-targeted polymers can be used to deliver DNA to the 
brain, but that it is likely to benefit from the addition of specific 
targeting moieties. Clearly DSP8 requires vast improvements, 
and is far from the CNS transfection efficiencies of adeno-
associated viruses such as those used in intracerebral clinical 
trials. DSP8 will therefore indeed require further modification 
if it is to deliver therapeutic genes with efficiencies capable of 
functional improvements in animal models of 
neurodegenerative diseases. However, the presence of vinyl 
functionality within the knot structure (Supplementary Figure 
S2) still allows the possibility of further modification (e.g. via 
standard click chemistry) with endcapping moieties,30 targeting 
peptides,29 or antibody fragments.31 Ongoing studies in our lab 
aim to create functionalised knot polymers specifically for 
enhanced neuronal transfection. 
Conclusions 
The simplicity of DE-ATRP for large scale synthesis of this 
knot structured polymer, the high transfection capability and 
the lack of toxicity demonstrates its use as a platform 
transfection technology. Analysis of the polymer degradation 
profile indirectly demonstrates the cleavable cyclized knot 
structure as the knot becomes “untied” when the intramolecular 
crosslinks are cleaved. DSP8 showed far lower levels of 
cytotoxicity than PEI with a ~20 fold difference in LC50 
values. Cytotoxicity analysis showed that the astrocyte viability 
remained above 80% when treated with DSP8 polyplexes at the 
weight ratios tested, compared with a decrease shown by both 
PEI and SuperFect® polyplexes. The transgene expression 
mediated by DSP8 supersedes that of PEI and Lipofectamine® 
2000, and continues up to four days post transfection at a level 
48 fold higher than PEI, 39 fold higher than the SuperFect® 
PAMAM dendrimer and 18 fold higher than the commonly 
used Lipofectamine® 2000. In summary, the good transfection 
profile and low cytotoxicity shown in astrocytes shows the 
potential of such a knot structure for gene delivery. 
Furthermore, the ease of this “one-pot” synthesis allows a 
variety of parameters such molecular weight, degree of 
PEGylation and moiety addition to be easily tailored for 
specific applications. 
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